Gentris Corporation Expands Headquarters, Biorepository Facility Grows to Meet Demand for Pharmacogenomics and Clinical Sample Storage
MORRISVILLE, N.C., Sept. 13, 2012 /PRNewswire/ -- Gentris Corporation (www.gentris.com), a global leader in pharmacogenomics and biorepository solutions, announced today the completion of a significant expansion to their Morrisville, N.C. facility. The first phase of the expansion included additional office space and a large, multipurpose conference room, which will accommodate scientific training and education programs. The second phase of construction tripled the available capacity of the clinical sample biorepository in order to meet future demand.
Gentris continues to invest in capabilities and capacity to address the growing personalized medicine market. As more pharmaceutical companies pursue biomarker-driven therapeutic strategies, there is a growing need to collect and store patient samples for analysis. The expanded biorepository will ensure sufficient capacity to accommodate the sample storage and management needs of pharmaceutical clients that are implementing pharmacogenomics in clinical trials. In addition to biorepository space, Gentris has added a large conference room to host scientific training and education programs that will focus on providing up-to-date information on best practices for integrating pharmacogenomics into drug development.
Eric Hall, Gentris VP of Clinical Operations and Biorepository Services, will be chairing a session on Strategic Specimen Tracking as part of the Biorepository track at the Clinical Business Expo 2012 in Boston on September 19-20.
Related Links: www.gentris.com
"As demand for clinical sample storage grows, we needed a larger, dedicated facility for sample management and biosrepository functions," said Eric Hall, Gentris VP of Clinical Operations and Biorepository. "Pharmaceutical companies are increasingly recognizing the value of banking clinical trial samples for immediate or future testing. By tripling the size of our biorepository space, we have increased our flexibility to manage and store a large number of diverse sample types and serve our rapidly expanding client base."
"We anticipate an increased need for biorepository and pharmacogenomics testing services as pharmaceutical companies invest in personalized medicine," said Scott Clark, Gentris Chief Scientific Officer. "The recent expansion will enable us to continue providing high quality solutions to our clients as well as to host training and education programs focused on maximizing the benefits of integrating pharmacogenomics and biobanking into clinical trials."
About Gentris Corporation:
Founded in 2001, Gentris is located in Research Triangle Park, NC, where it provides pharmacogenomics and biorepository support for all phases of clinical studies and genomic biomarker programs. The Company works with academic and industry leaders to translate innovations in pharmacogenomics into safer, more effective medicines, which can lead to accelerated drug development and improvement in patient care globally.
SOURCE Gentris Corporation